explore -WSS

explore

author：hotspot 2025-08-26 07:42:28 - browse：65413

US Capitol - SOTU — Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Chan Zuckerberg Biohub Chicago to focus on inflammation

explore

WSS

Sana to lay off nearly a third of staff, de

Covid silver lining: Unprecedented look at human immune system

AI can decode, harness the power of the humane immune system

Physician executives need more than on

Bristol 'take

Stroke deaths set to near 10 million globally by 2050

leisure time

explore

hotspot

Drug repurposing or repositioning? The language matters

Phenylephrine and the overlooked value of the placebo effect

How to save PrEP access — and even expand it

Harvard scientists, with Google, unveil the most detailed brain map ever

Sports medicine is finally prioritizing gender equality

Bill would stop addiction treatment from triggering child abuse inquiry

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Study: Black kids more likely to die after surgery than white kids

The high cost of giving birth even with insurance

Stroke deaths set to near 10 million globally by 2050

focus

Was Amgen transparent enough on FDA's concern on cancer drug?

A virus, fished out of a lake, may have saved a man’s life

Multiple sclerosis has subtypes with different best treatments: study

Scientists uncover potential path to treating deadly childhood tumor

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Senate panel eyes new effort on drug shortages

explore

leisure time

explore

Wikipedia